Akebia Therapeutics (AKBA) Total Non-Current Liabilities (2013 - 2026)

Akebia Therapeutics (AKBA) has 14 years of Total Non-Current Liabilities data on file, last reported at $334.5 million in Q1 2026.

• On a quarterly basis, Total Non-Current Liabilities rose 20.14% year-over-year to $334.5 million in Q1 2026; TTM through Mar 2026 was $334.5 million, a 20.14% increase from a year earlier, with the FY2025 full-year figure at $341.0 million, up 28.83% from the prior year.
• Total Non-Current Liabilities for Q1 2026 stood at $334.5 million, down from $341.0 million in the prior quarter.
• Over the last five years, Total Non-Current Liabilities for AKBA reached as high as $436.1 million in Q1 2022 and fell as low as $247.8 million in Q1 2024.
• Historically, Total Non-Current Liabilities has averaged $308.5 million across 5 years, with a median of $283.3 million in 2023.
• Across the five-year window, Total Non-Current Liabilities sank 35.04% in 2023 and rose 28.83% in 2025, its largest moves.
• Year by year, Total Non-Current Liabilities stood at $350.1 million in 2022, then dropped by 22.22% to $272.3 million in 2023, then retreated by 2.79% to $264.7 million in 2024, then advanced by 28.83% to $341.0 million in 2025, then declined by 1.91% to $334.5 million in 2026.
• Per Business Quant data, the three most recent Total Non-Current Liabilities figures were $334.5 million in Q1 2026, $341.0 million in Q4 2025, and $317.6 million in Q3 2025.